Hospital Clinic Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (16)

2019

  1. Recommendations from a panel of experts on the usefulness of fidaxomicin for the treatment of infections caused by Clostridium difficile

    Revista Espanola de Quimioterapia, Vol. 32, Núm. 1, pp. 50-59

2017

  1. Epidemiology and prognosis of candidaemia in elderly patients

    Mycoses, Vol. 60, Núm. 12, pp. 808-817

  2. Etestw versus broth microdilution for ceftaroline MIC determination with Staphylococcus aureus: Results from PREMIUM, a European multicentre study

    Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 2, pp. 431-436

  3. Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia

    Clinical Microbiology and Infection, Vol. 23, Núm. 1, pp. 49.e1-49.e8

  4. Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance

    Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11

  5. The efficacy of fidaxomicin in the treatment of Clostridium difficile infection in a real-world clinical setting: a Spanish multi-centre retrospective cohort

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 2, pp. 295-303

2016

  1. Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort

    Clinical Microbiology and Infection, Vol. 22, Núm. 8, pp. 733.e1-733.e8

2015

  1. A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains

    Clinical Microbiology and Infection, Vol. 21, Núm. 7, pp. 684.e1-684.e9

  2. Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance

    Journal of Infection, Vol. 71, Núm. 3, pp. 385-394

  3. Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: RESULTS from a population-based surveillance in Spain

    Clinical Microbiology and Infection, Vol. 21, Núm. 5, pp. 491.e1-491.e10

2014

  1. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: A population-based surveillance in Spain

    Clinical Microbiology and Infection, Vol. 20, Núm. 4

2012

  1. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric sensititre yeastone method

    Journal of Clinical Microbiology, Vol. 50, Núm. 12, pp. 3921-3926

  2. Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 5, pp. 1181-1187

2011

  1. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia

    Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 12, pp. 5590-5596

2010

  1. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain

    Journal of Clinical Microbiology, Vol. 48, Núm. 11, pp. 4200-4206

2008

  1. Staphylococcus spp. en España: Situación actual y evolución de la resistencia a antimicrobianos (1986-2006)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 26, Núm. 5, pp. 269-277